MQS Management LLC Purchases 1,614 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

MQS Management LLC boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 30.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,897 shares of the company’s stock after acquiring an additional 1,614 shares during the period. MQS Management LLC’s holdings in Henry Schein were worth $442,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of HSIC. Norges Bank purchased a new stake in shares of Henry Schein during the 4th quarter valued at $111,715,000. PNC Financial Services Group Inc. raised its stake in Henry Schein by 5.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 87,085 shares of the company’s stock valued at $6,593,000 after buying an additional 4,591 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Henry Schein by 1.0% in the fourth quarter. Corient Private Wealth LLC now owns 55,741 shares of the company’s stock worth $4,220,000 after acquiring an additional 542 shares in the last quarter. SageView Advisory Group LLC purchased a new stake in shares of Henry Schein during the fourth quarter worth about $285,000. Finally, Hsbc Holdings PLC increased its holdings in shares of Henry Schein by 18.1% during the fourth quarter. Hsbc Holdings PLC now owns 267,587 shares of the company’s stock valued at $20,228,000 after acquiring an additional 41,087 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The sale was disclosed in a filing with the SEC, which is available at this link. 1.14% of the stock is currently owned by company insiders.

Henry Schein Price Performance

NASDAQ:HSIC opened at $72.54 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.55 and a quick ratio of 0.90. The company has a 50 day moving average price of $69.77 and a 200-day moving average price of $70.42. Henry Schein, Inc. has a 1-year low of $60.01 and a 1-year high of $82.63. The firm has a market cap of $9.29 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 1.88 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The company had revenue of $3.10 billion during the quarter, compared to analysts’ expectations of $3.27 billion. During the same quarter in the previous year, the company earned $1.31 earnings per share. The firm’s revenue for the quarter was up .0% on a year-over-year basis. Equities research analysts forecast that Henry Schein, Inc. will post 4.75 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HSIC. Evercore ISI dropped their target price on shares of Henry Schein from $72.00 to $70.00 and set an “in-line” rating on the stock in a research report on Wednesday, August 7th. Piper Sandler reissued an “overweight” rating and issued a $86.00 target price on shares of Henry Schein in a research report on Friday, June 21st. Barrington Research lowered their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Baird R W raised Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. Finally, UBS Group reduced their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $77.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.